Research Article

Descriptive Epidemiology of Brain and Central Nervous System Tumours: Results from Iran National Cancer Registry, 2010-2014

Amir Salimi,1 Alireza Zali,2 Amir Saeid Seddighi,2 Afsoun Seddighi,2 Shakila Meshkat,3 Morteza Hosseini,2 Amir Nikouei,2 and Mohammad Esmaeil Akbari1

1Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Functional Neurosurgical Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Mohammad Esmaeil Akbari; drakbari.drakbari@gmail.com

Received 3 April 2020; Revised 22 July 2020; Accepted 5 August 2020; Published 18 September 2020

Academic Editor: Eleanor Kane

Copyright © 2020 Amir Salimi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Central nervous system (CNS) tumours account for only 1-2% of cancer incidence but are a major reason for mortality and morbidity due to malignancies. Recent studies show an increase in the rate of CNS tumours worldwide, especially in developing countries. Moreover, there is significant heterogeneity in epidemiological patterns worldwide. This study is aimed at representing nationwide epidemiology of CNS tumours in Iran.

Methods. Iran National Cancer Registry 2010-2014 data were reviewed for CNS tumours. The epidemiological rates were calculated for both genders and all age groups using the 2011 census information.

Results. Out of 17345 cases, 58.5% were men and 41.5% were women. The mean age was 45.55 years ranging from less than 1 month to 100 years old. Average total age-standardized incidence rate (ASR) was 5.19 for primary tumours. The annual percent change (APC) was 14.23% during the study period. The most frequent site and histology recorded were brain, NOS and diffuse astrocytic, respectively. Geographical distribution showed about five-fold difference in ASRs between different provinces.

Conclusion. The overall ASR calculated was higher than the global rate in 2012 but lower than that of most developed countries, showing an increasing trend which may be due to either advances in diagnosing or risk factor augmentation. The mean age and incident rates were higher than those of previous reports in Iran.

1. Introduction

Central nervous system (CNS) tumours are much less prevalent, accounting for only 1-2% of the total cancer incidence. However, they represent a major source of mortality and morbidity [1–3]. In the United States, CNS cancers represent 1.4% of newly diagnosed cancers and 2.7% of cancer mortality [4]. Recent studies show an increase in the prevalence of CNS tumours worldwide [2, 5]. Based on the most recent estimates, each year, more than 296000 new cases (1.6% of overall cancer incidence) are diagnosed worldwide, and more than 241000 individuals die due to CNS tumours (2.5% of overall cancer mortality) [1, 6, 7] with men showing a higher incidence rate (IR) (4.2 in 100000 inhabitants) than that of women (3.6 in 100000 inhabitants) [6]. The IR of all primary CNS tumours ranges from 17.6/105 to 22.0/105 in America [8] and Europe [7, 9, 10].

Central nervous system tumour is typically defined as brain and spine tumours; however, the International Classification of Diseases for Oncology third edition (ICD-O-3) defines meninges, pineal gland, pituitary gland, and nerves as CNS tumours as well [11].

There is significant heterogeneity in the epidemiology, incidence, mortality, and histological spectrum of CNS tumours across different regions of the world [3, 12]. The probable reason for such differences in epidemiologic patterns is yet unclear, but differences in environment, genetics, culture, age, and access to health resources could be considered [1, 2]. Comprehensive and systematic epidemiological studies can further our knowledge of such influences worldwide.

Developed countries conducted a number of comprehensive epidemiological studies on CNS tumours [5, 8, 13–17]. In contrast, in developing countries including Iran [18–20],
scattered studies have been conducted. There are not any comprehensive nationwide studies in this area [21–28]. Thus, in the current study, we aimed to present a nationwide CNS tumour epidemiology for all age groups in all provinces of Iran as well as the epidemiologic trend during the study period based on Iran National Cancer Registry (INCR) data.

2. Material and Methods

2.1. Data Source. The study included patients who were diagnosed with central nervous system cancer from 2010 to 2014. The patients were identified by ICD-O-3 codes (Tables 1 and 2) through the Iran National Cancer Registry. National cancer registry raw data were reviewed for all registered CNS tumours from 2010 to 2014. Based on histology reports, some of the patients were categorized as “secondary tumours” and “undetermined secondary or primary” but most of the patients were categorized as “primary tumours” and we focused on them in our study. Reporting benign CNS tumours is not compulsory and systematic yet, but if reported by a center, they would be involved in the INCR data.

2.2. Design. We conducted a nationwide population-based study on national cancer registry data on CNS tumours over 5 years from 2010 to 2014. Duplicate cases were first identified according to patients’ names, family, tumour type, tumour location, and sex, then were excluded from the study. Data were categorized based on WHO classification of CNS tumours histologies reported by Louis et al. [29]. Population data were obtained from the last 2011 census On the National Institute of Statistics of Iran webpage (https://amar.org.ir/), and the Segi-Doll standard population data were obtained from The Global Cancer Observatory (GCO) website [30] to perform ASR calculations.

2.3. Statistical Analysis. Categorical data are presented as numbers and percentages. To compare categorical and continuous data between male and female groups, chi-squared and independent-sample t-tests were applied.

The last 2011 census of population information was used to calculate (age- and gender-specific) crude incidence rates (CIRs) per 100000 individuals. To obtain annual incidence rates from 2010 to 2014, the estimated midyear population was used as denominator. The Segi-Doll standard population data were used to calculate age-standardized rates (ASRs) by the direct standardization method.

The incidence rates are presented with 95% confidence interval (95% CI). To investigate the trend of the rates during this period of time, a log-linear model was fitted and the average annual percent change (APC) was calculated based on the model parameter [31]. All calculations and statistical analysis were carried out using Microsoft Excel 2013 and R statistical software, version 3.2.1. The significance level was set at 0.05.

2.4. Ethical Approval. This study was approved by the Shahid Beheshti University of Medical Sciences Ethics Committee.

Table 1: ICD-O-3 topography (site) codes.

| Site                      | ICD-O-3 site codes |
|--------------------------|--------------------|
| Meninges                 | C70.0, C70.1, C70.9 |
| Cerebrum                 | C71.0              |
| Frontal lobe of brain    | C71.1              |
| Temporal lobe of brain   | C71.2              |
| Parietal lobe of brain   | C71.3              |
| Occipital lobe of brain  | C71.4              |
| Ventricle                | C71.5              |
| Cerebellum               | C71.6              |
| Brainstem                | C71.7              |
| Overlapping lesion of brain | C71.8           |
| Brain, NOS               | C71.9              |
| Spinal cord              | C72.0              |
| Cauda equina             | C72.1              |
| Cranial nerves           | C72.2, C72.3, C72.4, C72.5 |
| Overlapping lesion of brain and central nervous system | C72.8 |
| Nervous system, NOS      | C72.9              |

3. Results

3.1. Overall Incidence. In this study, we reviewed 17345 incident cases of CNS tumours from 2010 to 2014. Only 50.4% of data were microscopically verified (MV). Out of 17345 cases, 10151 were men (58.5%) and 7194 were women (41.5%).

Based on the nature of tumours, we divided them into three major groups: (i) primary, (ii) secondary, and (iii) undetermined whether secondary or primary (SorP). The mean age at diagnosis for patients in the primary, secondary, and undetermined groups was 45.54 ± 21.46, 49.78 ± 19.17, and 35.44 ± 21.95, respectively, with a statistically significant difference between them (p value < 0.001).

The highest average ASR during the study period was observed among primary tumours (5.19; 95% CI (4.99-5.38)) in both men (5.56 (5.41-5.71)) and women (3.93 (3.81-4.06)). Secondary and secondary or primary (SorP) had ASRs of 0.21 and 0.04, respectively. Annex 1 shows the number of patients in the study period in each age category separated by gender. Patients under 1 year of age are presented separately due to the importance of CNS tumours in this group of patients. Annex 2 depicts the annual age-specific CIR and the number of patients per year from 2010 to 2014 and the average CIR during the entire study period. Hereafter, all rates and reports are for 16547 primary tumour cases.

Mean age at diagnosis was 45.54 (SD = 21.45); the oldest patient was 100 years old and the youngest patient was a neonate. Out of 16547 cases, only 8115 (51.1%) were microscopically verified, 9695 (58.6%) were male, and 6852 (41.4%) were female.

3.2. Age-Standardized and Gender-Specific Incidence Rate of Primary Tumours. Table 3 depicts the annual ASRs and the number of patients per year from 2010 to 2014 and the average ASR during the entire study period. The average ASR was 5.19 (4.99-5.38) per 100000 individuals per
year. The highest CIR among age groups was 16.25 (for the 75-79 year group) and the lowest was 1.34 (for the 10-14 year-old age group). The annual CIR and the average CIRs are presented by age group in Annex 2. The annual CIR and the average CIRs were depicted by age group and gender in Figure 1.

The total ASR of primary tumours in the entire study period was 5.19 (4.99-5.38), and the total ASRs were 5.56 (5.41-5.71) and 3.93 (3.81-4.06) for men and women, respectively (Table 3). The ASR increased from 3.43 (3.33-3.54) in 2010 to 5.60 (5.47-5.72) in 2014. According to the Poisson regression model result, a significant rising trend was observed in the total ASR rates during this period ($p = 0.001$ for trend). The annual percent change (APC) was 14.23% during the study period. The ASR changed from 3.96 (3.84-4.07) in 2010 to 6.48 (6.34-6.62) in 2014 for men and from 2.92 (2.82-3.01) in 2010 to 4.76 (4.64-4.88) in 2014 for women. During the study period, there was no statistically significant trend of ASR among men ($p = 0.211$), but an increasing trend of ASR was observed among women ($p < 0.001$). APC was 14.32% and 14.25% for men and women, respectively.

### Table 2: ICD-O-3 histology codes.

| Histology                                             | ICD-O-3 histology codes                                      |
|-------------------------------------------------------|-------------------------------------------------------------|
| Diffuse astrocytic and oligodendrogial tumours        | 9380, 9382, 9400, 9401, 9411, 9440, 9441, 9442, 9450, 9451  |
| Other astrocytic tumours                              | 9421, 9424                                                  |
| Ependymal tumours                                     | 9383, 9391, 9392, 9393                                      |
| Other gliomas                                         | 9430                                                       |
| Choroid plexus tumours                                | 9390                                                       |
| Embryonal tumours                                     | 9470, 9471, 9473, 9474, 9490, 9500, 9501, 9502, 9521        |
| Tumours of cranial and paraspinal nerves              | 9560, 9540                                                  |
| Meningioma                                            | 9530, 9531, 9534, 9537, 9538                                 |
| Mesenchymal, nonmeningothelial tumours                | 8802, 8810, 8815, 8850, 8851, 8890, 8900, 9120, 9133, 9140, 9161, 9170, 9180, 9220, 9240, 9243, 9364, 9370, 9371 |
| Melanocytic tumours                                   | 8720                                                       |
| Lymphomas                                             | 9590, 9591, 9596, 9670, 9675, 9680, 9684, 9699, 9702        |
| Germ cell tumours                                     | 9060, 9064, 9065, 9071, 9080, 9081, 9085,                  |
| Others                                                | 9505, 9750                                                  |
| Unspecified                                           | 8000, 8001                                                  |

### Table 3: Distribution of tumours in different sites (topography) and patients’ mean age.

| Location                              | Total number (%) | Male mean age | Female mean age | p value |
|---------------------------------------|------------------|---------------|-----------------|---------|
| Meninges                              | 408 (2.5%)       | 53.4          | 50              | 0.09    |
| Cerebrum                              | 521 (3.1%)       | 43.4          | 40.8            | 0.18    |
| Frontal lobe                          | 1316 (8%)        | 44.7          | 45.6            | 0.37    |
| Temporal lobe                         | 1039 (6.3%)      | 46.9          | 45.2            | 0.16    |
| Parietal lobe                         | 823 (5%)         | 47.9          | 46.7            | 0.35    |
| Occipital lobe                        | 182 (1.1%)       | 49.5          | 44.1            | 0.05    |
| Ventricle                             | 147 (0.9%)       | 35.5          | 38              | 0.47    |
| Cerebellum                            | 633 (3.8%)       | 29.2          | 33.1            | 0.03    |
| Brainstem                             | 182 (1.1%)       | 31            | 25.6            | 0.09    |
| Brain, NOS                             | 8968 (54.2%)     | 46.2          | 46.2            | 0.84    |
| Spinal cord                           | 515 (3.1%)       | 42.3          | 44.5            | 0.24    |
| Cranial nerves                        | 34 (0.2%)        | 40.4          | 32.2            | 0.36    |
| Overlapping brain and central nervous system | 45 (0.3%)   | 52.4          | 49.6            | 0.66    |
| Missing                               | 200 (1.2%)       | 43.7          | 40.5            | 0.32    |
| Overlapping brain                     | 382 (2.3%)       | 47            | 44.5            | 0.20    |
| Cauda equina                          | 7 (0.04%)        | 43.7          | 46              | 0.91    |
| Nervous system, NOS                   | 1145 (6.9%)      | 51.8          | 51.2            | 0.67    |
3.3. Tumour Site (Topography). The most common recorded sites are as follows: brain, NOS; frontal lobe; nervous system, NOS; and temporal lobe. Each comprise 54.2%, 8%, 6.9%, and 6.3% of all data, respectively. A statistically significant difference was observed between the genders’ distribution of tumour location regarding the frontal lobe, temporal lobe, parietal lobe, meninges, and brainstem. Men had significantly more tumours in the frontal lobe, temporal lobe, and parietal lobe, and women had more tumours in the brainstem and meninges ($p < 0.05$). Men with tumours in the occipital lobe were significantly older than women ($p < 0.05$), while women with tumours in the cerebellum were significantly older than men ($p < 0.05$). Table 4 shows the mean age and number of patients based on tumour location in both genders with a significant difference between females and males in the occipital lobe and cerebellum.

3.4. Tumour Histology. The number of patients and ASRs are presented in Table 5. The most common histology subgroups are diffuse astrocytic (48.36%), unspecified malignancy (32.32%), and embryonal tumours (4.55%) with ASRs of 2.40, 2.04, and 0.23, respectively.
3.5. Geographic Distribution. Table 6 and Figure 2 show the geographical distribution of CNS tumours in all 31 provinces of Iran based on their average ASRs. Unlike other provinces, the Qom province showed a female predominance. Kohgiluyeh and Boyer-Ahmad and Bushehr provinces had male to female ratios higher than 2, and Qom showed a female predilection in the number of patients.

4. Discussion

In this study, we aimed to provide nationwide descriptive epidemiology of CNS tumours among the Iranian population using INCRR data. ASRs were calculated using the Segi-Doll standard population to make comparisons more feasible. Hasanpour-Heidari et al. reported completeness of 96.3% for CNS tumours in Golestan province, which was the best rate among other groups of tumours. Mohammadi et al. reported INCRR completeness of 71.2% and 59.9% for men and women, respectively, regarding all types of registered tumours [32, 33].

The average ASR for all primary CNS tumours registered from 2010 to 2014 was 5.19 (4.99-5.38) per 100000 individuals per year, which was higher than the 2012 global rate of 3.4 [31]. However, our national 2014 ASR increased to 5.19, which was higher than the global rate in 2016 but lower than most developed countries’ rates [1, 2, 5, 8, 13, 14, 34]. During 2010-2014, average ASRs were 5.56 and 3.93 for men and women, respectively. Miranda-Filho et al. applied data from 96 registries in 39 countries to evaluate CNS tumours in adults (>15 y); Brazil, Croatia, Thailand, and Uganda showed the highest ASR for men (=13.3), highest ASR for women (=12), lowest ASR for men (=2.4), and lowest ASR for women (=1), respectively [35].

CNS tumours’ ASR demonstrated an annual percentage change of 14.23% during the study period. This incidence surge and a high APC in Iran like other developing countries could be attributed to advances in neuroimaging, neuropathology, and neurosurgery [36–38] or changes in lifestyle, population pyramid, and stronger registration over time [35, 39]. Other reports from Iran reported high APC rates; Darabi et al. reported an APC of 16.7% and 20% for stomach tumours and colorectal tumours, respectively [40]. Leukemia incidence APC was 19.9% in Koohi et al.’s evaluation [41], and Pakzad et al. calculated an APC of 17.3% for prostate tumours [42].

Higher CT scan utilization leads to more diagnosis, and it also has more ionizing emissions than plain radiographs [43] and shows association with CNS tumours [44]. A recent report showed that the number of CT scans performed per each emergency room visit in an Iranian hospital in 2016 was about three times higher than world rates [45].

Although the highest rates of CNS tumours were observed in high-middle followed by the high quintile socio-demographic index (SDI), developed countries had negative APC rates in their recent evaluations [2, 34], which comes after high APC rates in the late 20th century. Such decreasing rates might be the result of development in early diagnosis and availability of more efficient treatments for nonmalignant tumours or the separation of nonmalignant tumours in recent studies [35].

In a systematic review of primary CNS tumours in Iran from 2000 to 2009, performed by Jazayeri et al., the ASRs were 4.16 for men and 3.46 for women [23]; these are lower than the ASRs in our study which show an ascending trend. Jordan represented a total crude incidence rate of 5.01 for all malignant and nonmalignant CNS tumours in 2011 and 2012 [19].

The mean age at diagnosis was 45.54 years in our study which is higher than that of other studies in Iran [21, 23–27] and Jordan [19] but is lower than that of other developed countries which seems to be related to population structure changes. The preponderance of males among CNS tumour patients in our study is in accordance with the global estimates in 2012 (1.41 compared with 1.2 m/f ratio) [31] and the estimates in most of other studies in the world that represent male to female ratios between 1 and 2.7 [35]; however, some studies showed female predominance similar to Qom province [19, 22, 46]. The possible hypothesis for male preponderance is sex hormones and adverse working conditions such as exposure to chemicals and pesticides [47].

Our findings on the histology of tumours are not possibly conclusive enough due to notably high rates of unspecified tumours (mostly M 8000.3 and M 8001.3 codes), which are likely a reflection of lack of advanced diagnostic facilities particularly in rural areas that indicates high rates of astrocytic and oligodendroglioma tumours. These findings are in line with
|                  | Male      |        |         | Female   |        |         | Total    |        |
|------------------|-----------|--------|---------|----------|--------|---------|----------|--------|
|                  | N         | %      | ASR     | N        | %      | ASR     | N        | %      | ASR     | 95% CI  |
| Primary tumours  | 9695      | 95.51  | 5.56    | 6852     | 95.25  | 3.93    | 16547    | 95.40  | 5.19    | 4.99-5.38 |
| Diffuse astrocytic and other oligodendroglial tumours | 5144      | 50.68  | 2.88    | 3244     | 45.09  | 1.81    | 8388     | 48.36  | 2.40    | 2.30-2.50 |
| Others           | 12        | 0.11   | 0.007   | 3        | 0.042  | 0.002   | 15       | 0.087  | 0.004   | 0.002-0.008 |
| Embryonal tumour | 474       | 4.67   | 0.27    | 315      | 4.38   | 0.19    | 789      | 4.55   | 0.23    | 0.20-0.027 |
| Meningioma       | 160       | 1.58   | 0.084   | 217      | 3.02   | 0.117   | 377      | 2.17   | 0.12    | 0.12-0.14 |
| Mesenchymal      | 77        | 0.759  | 0.04    | 46       | 0.639  | 0.02    | 123      | 0.709  | 0.04    | 0.02-0.05 |
| Melanocytic tumour| 11       | 0.109  | 0.006   | 5        | 0.070  | 0.003   | 16       | 0.092  | 0.003   | 0.001-0.006 |
| Lymphomas        | 268       | 2.649  | 0.15    | 205      | 2.85   | 0.12    | 473      | 2.73   | 0.16    | 0.12-0.18 |
| Germ cell        | 24        | 0.236  | 0.013   | 20       | 0.278  | 0.011   | 44       | 0.254  | 0.012   | 0.005-0.020 |
| Unspecified malignancy | 3130   | 30.83  | 1.87    | 2475     | 34.40  | 1.45    | 5605     | 32.32  | 2.03    | 1.88-2.18 |
| Other astrocytic tumours | 32  | 0.315  | 0.016   | 27       | 0.375  | 0.013   | 59       | 0.340  | 0.015   | 0.008-0.022 |
| Other gliomas    | 8         | 0.079  | 0.005   | 7        | 0.097  | 0.003   | 15       | 0.087  | 0.004   | 0.001-0.008 |
| Ependymal tumour | 335       | 3.30   | 0.17    | 273      | 3.780  | 0.13    | 608      | 3.51   | 0.17    | 0.14-0.20 |
| Choroid plexus tumour | 12  | 0.118  | 0.01    | 6        | 0.083  | 0.003   | 18       | 0.104  | 0.006   | 0.001-0.011 |
| Cranial and paraspinal nerve tumours | 8    | 0.079  | 0.004   | 9       | 0.125  | 0.004   | 17       | 0.098  | 0.004   | 0-0.0001 |
| Secondary tumour | 375       | 3.69   | 0.23    | 286      | 3.98   | 0.17    | 661      | 3.81   | 0.21    | 0.18-0.25 |
| Primary or secondary tumours | 81 | 0.798  | 0.049   | 56       | 0.779  | 0.031   | 137      | 0.790  | 0.042   | 0.027-0.057 |

*ASR: age-standardized incidence rate (per 10^5 inhabitants per year).*
previous studies conducted in Iran [22, 25, 27]. Lack of a
unanimous tumour diagnosis even by skillful pathologists is
another reason behind the high rates of unspecified tumours.
Another difficulty was in the data analysis phase of the pro-
ject; we found histology codes that could not be considered
primary (adenocarcinomas). Thus, to avoid underestimation,
such codes were first categorized into a secondary tumour
or primary/secondary group and then included in
our total calculations. However, we reported primary
tumours rates separately to make comparisons with other
studies unchallenging for readers.

There was a noticeable difference in incidence rates in
different provinces across the country; Yazd province had
an ASR of 9.86 per 100000 individuals per year, and Qom
province had an ASR of 1.85 per 100000 individuals per year.

It showed more than five-fold difference between them, simi-
lar to the difference that was observed between different
regions in the world [35] and Roshandel et al.’s study of can-
cer incidence in Iran in 2014 [48]. This result could likely be
due to many factors such as differences in the availability of
medical facilities, genetics, lifestyle, environmental, and
many other probable factors that should be considered in
future studies.

There is not enough information on the etiology of CNS
tumours except genetics and ionizing radiations as risk
factors and a possible carcinogen with unknown ef-
fects. Moreover, allergic reactions can decrease the risk of CNS
tumours [49, 50]. Therefore, more comprehensive epidemi-
ological studies are needed to find out the relationship between
potential etiologies and epidemiologic diversities.

Table 6: Geographical distribution of CNS tumours by provinces.

| Region              | Province                  | Male | ASR Female | Total | Male | ASR Female | Total | Number | Male | Female | Total | M/F ratio | Mean age |
|---------------------|---------------------------|------|------------|-------|------|------------|-------|--------|------|--------|-------|------------|----------|
| North/North West    | Ardebil                   | 4.72 | 4.04       | 4.61  | 132  | 104        | 236   | 1.3    | 42.5 |        |       |            |          |
|                     | Golestan                  | 3.59 | 2.54       | 3.20  | 134  | 87         | 221   | 1.5    | 43.5 |        |       |            |          |
|                     | Guilan                    | 4.89 | 4.09       | 4.73  | 324  | 245        | 569   | 1.3    | 52.4 |        |       |            |          |
|                     | Mazandaran                | 2.85 | 1.98       | 2.41  | 213  | 153        | 366   | 1.4    | 44.9 |        |       |            |          |
|                     | North Khorasan            | 4.56 | 3.38       | 4.48  | 72   | 60         | 132   | 1.2    | 44.5 |        |       |            |          |
|                     | East Azarbaijan           | 2.72 | 2.37       | 2.85  | 258  | 225        | 483   | 1.1    | 49.9 |        |       |            |          |
|                     | Kordestan                 | 4.29 | 3.64       | 3.95  | 156  | 124        | 280   | 1.3    | 43.8 |        |       |            |          |
|                     | West Azarbaijan           | 4.01 | 3.09       | 3.54  | 276  | 221        | 497   | 1.2    | 46.6 |        |       |            |          |
|                     | Zanjan                    | 3.87 | 3.20       | 3.53  | 96   | 79         | 175   | 1.2    | 44.1 |        |       |            |          |
| West                | Hamedan                   | 4.27 | 3.32       | 3.80  | 189  | 128        | 317   | 1.5    | 46   |        |       |            |          |
|                     | Ilam                      | 3.16 | 1.68       | 2.52  | 37   | 20         | 57    | 1.9    | 52.3 |        |       |            |          |
|                     | Kermanshah                | 3.85 | 1.83       | 2.39  | 131  | 88         | 219   | 1.5    | 43   |        |       |            |          |
|                     | Khouzestan                | 6.55 | 4.89       | 5.84  | 623  | 452        | 1075  | 1.4    | 43.1 |        |       |            |          |
|                     | Lorestan                  | 7.08 | 4.69       | 6.06  | 273  | 172        | 445   | 1.6    | 46.3 |        |       |            |          |
| Center              | Alborz                    | 4.67 | 2.61       | 3.71  | 262  | 137        | 399   | 1.9    | 48.5 |        |       |            |          |
|                     | Chaharmahal and Bakhtiari | 3.34 | 2.25       | 2.89  | 65   | 47         | 112   | 1.4    | 41.4 |        |       |            |          |
|                     | Qazvin                    | 3.49 | 2.28       | 2.88  | 95   | 63         | 158   | 1.5    | 46.5 |        |       |            |          |
|                     | Isfahan                   | 6.87 | 5.27       | 6.35  | 808  | 568        | 1376  | 1.4    | 50.6 |        |       |            |          |
|                     | Kerman                    | 4.82 | 3.76       | 4.32  | 292  | 234        | 526   | 1.2    | 44.1 |        |       |            |          |
|                     | Kohgiluyeh and Booyer Ahmad | 4.84 | 2.89   | 3.87  | 78   | 39         | 117   | 2      | 34.9 |        |       |            |          |
|                     | Markazi                   | 8.46 | 6.15       | 7.29  | 305  | 217        | 522   | 1.4    | 51.9 |        |       |            |          |
|                     | Semnan                    | 5.28 | 4.12       | 4.69  | 79   | 58         | 137   | 1.4    | 50   |        |       |            |          |
|                     | Tehran                    | 5.33 | 3.71       | 4.52  | 1618 | 1098       | 2716  | 1.5    | 45.1 |        |       |            |          |
|                     | Yazd                      | 10.45| 9.33       | 9.86  | 270  | 229        | 499   | 1.2    | 48.3 |        |       |            |          |
|                     | Qom                       | 1.51 | 2.09       | 1.85  | 43   | 52         | 95    | 0.8    | 45.9 |        |       |            |          |
| East                | Razavi Khorasan           | 6.31 | 4.74       | 5.59  | 838  | 615        | 1453  | 1.4    | 44.7 |        |       |            |          |
|                     | Sistan and Baluchestan    | 2.75 | 2.12       | 2.44  | 126  | 91         | 217   | 1.4    | 37.2 |        |       |            |          |
| South Khorasan      | 3.42 | 2.20       | 2.81  | 48    | 31   | 79         | 1.5    | 41.5 |        |       |            |          |
| South               | Bushehr                   | 3.83 | 1.76       | 2.83  | 88   | 36         | 124   | 2.4    | 40.6 |        |       |            |          |
|                     | Fars                      | 8.31 | 6.24       | 7.47  | 886  | 626        | 1512  | 1.4    | 46.7 |        |       |            |          |
|                     | Hormozgan                 | 2.77 | 2.42       | 2.58  | 91   | 78         | 169   | 1.2    | 38.9 |        |       |            |          |
| Unknown             |                           | 0.46 | 0.27       | 0.37  | 789  | 475        | 1264  | 1.7    | 34.1 |        |       |            |          |
Figure 2: Geographical distribution of CNS tumours by provinces in the total population (a), in the female population (b), and in the male (c) population.
Data Availability

Data are available on demand for those who meet our criteria.

Additional Points

Key Points. Average total age-standardized incidence rate (ASR) was 5.19 for primary tumours. The annual percent change was 13.69% during the study period. Geographical distribution showed five-fold difference in ASR among provinces.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors acknowledge the Iran National Cancer Registry and Cancer Research Center and their staff for their kind contribution to data gathering.

Supplementary Materials

Annex 1: depicts the number of patients in each age group by gender in the whole study on an age-gender pyramid. Annex 2: includes crude incidence rates by age groups and year. (Supplementary Materials)

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] V. L. Feigin, E. Nichols, T. Alam et al., “Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016,” The Lancet Neurology, vol. 18, no. 1, pp. 459–480, 2019.
[3] T. Gupta, R. Achari, A. Chatterjee et al., “Comparison of epidemiology and outcomes in neuro-oncology between the east and the west: challenges and opportunities,” Clinical Oncology (Royal College of Radiologists), vol. 31, no. 8, pp. 539–548, 2019.
[4] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016.
[5] C. Pouchieu, A. Gruber, E. Bertaud et al., “Increasing incidence of central nervous system (CNS) tumors (2000–2012): findings from a population based registry in Gironde (France),” BMC Cancer, vol. 18, no. 1, pp. 653–653, 2018.
[6] F. Bray, M. Colombet, L. Mery et al., Cancer Incidence in Five Continents, Vol. XI (electronic version), Lyon, IARC, 2017, http://ci5.iarc.fr last accessed on [August 14, 2020].
[7] R. Stupp, W. P. Mason, M. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005.
[8] Q. T. Ostrom, H. Gittleman, J. Fulop et al., “CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012,” Neuro-Oncology, vol. 17, Supplement 4, pp. iv1–iv62, 2015.
[9] L. Hardell, M. Carlberg, F. Soderqvist, and K. H. Mild, “Case-control study of the association between malignant brain tumours diagnosed between 2007 and 2009 and mobile and cordless phone use,” International Journal of Oncology, vol. 43, no. 6, pp. 1833–1845, 2013.
[10] D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007.
[11] A. Fritz, Percy Constance et al., International Classification of Diseases for Oncology, World Health Organization, 3rd edition, 2000.
[12] M. L. Bondy, M. E. Scheurer, B. Malmer et al., “Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium,” Cancer, vol. 113, no. 57, pp. 1953–1968, 2008.
[13] R. H. Dahlrot, F. R. Poulsen, N. N. T. T. Nguyen et al., “Trends in tumours in the central nervous system in elderly in Denmark, 2008-2012,” Acta Oncologica, vol. 55, Supplement 1, pp. 91–97, 2016.
[14] A. Darlix, S. Zouaoui, V. Bigau et al., “Epidemiology for primary brain tumors: a nationwide population-based study,” Journal of Neuro-Oncology, vol. 131, no. 3, pp. 525–546, 2017.
[15] C. H. Lee, K. W. Jung, H. Yoo, S. Park, and S. H. Lee, “Epidemiology of primary brain and central nervous system tumors in Korea,” Journal of Korean Neurosurgical Association, vol. 48, no. 2, pp. 145–152, 2010.
[16] E. V. Walker, F. G. Davis, CBTR founding affiliates et al., “Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013,” Neuro-Oncology, vol. 21, no. 3, pp. 360–369, 2019.
[17] A. Philips, D. L. Henshaw, G. Lamburn, and M. J. O’Carroll, “Brain Tumours: Rise in Glioblastoma Multiforme Incidence in England 1995–2015 Suggests an Adverse Environmental or Lifestyle Factor,” Journal of Environmental and Public Health, vol. 2018, Article ID 7910754, 10 pages, 2018.
[18] E. Jedy-Agba, M. P. Curado, O. Ogunbiyi et al., “Cancer incidence in Nigeria: a report from population-based cancer registries,” Cancer Epidemiology, vol. 36, no. 5, pp. e271–e278, 2012.
[19] A. F. Tamimi, I. Tamimi, M. Abdelaziz et al., “Epidemiology of malignant and non-malignant primary brain tumors in Jordan,” Neuroepidemiology, vol. 45, no. 2, pp. 100–108, 2015.
[20] N. Manoharan, P. K. Julla, and G. K. Rath, “Descriptive epidemiology of primary brain and CNS tumors in Delhi, 2003–2007,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 2, pp. 637–640, 2012.
[21] S. Beygi, S. Saadat, S. B. Jazayeri, and V. Rahimi-Movaghar, “Epidemiology of pediatric primary malignant central nervous system tumors in Iran: a 10 year report of National Cancer Registry,” Cancer Epidemiology, vol. 37, no. 4, pp. 396–401, 2013.
[22] K. Askari, S. Janeshin, M. Mashouf, M. Taherzadeh-Amlashi, and S. M. Seyed-Saadat, “Central nervous system tumors in Gilan, Iran: epidemiological features over 10 years,” Caspian Journal of Neurological Sciences, vol. 1, no. 1, pp. 19–26, 2015.
[23] S. B. Jazayeri, V. Rahimi-Movaghar, F. Shokraneh, S. Saadat, and R. Ramezani, “Epidemiology of primary CNS tumors in Iran: a systematic review,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 6, pp. 3979–3985, 2013.
